8 assets in Idiopathic Inflammatory Myopathy

Therapeutic assets addressing Idiopathic Inflammatory Myopathy, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Filgotinib Idiopathic Inflammatory Myopathy	UMC Utrecht	P2	CCC (53)
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy Idiopathic Inflammatory Myopathy	Beijing Boren Hospital	P1	CC (43)
azd0120 Idiopathic Inflammatory Myopathy	AstraZeneca	P1	CC (43)
hbi0101 cart Idiopathic Inflammatory Myopathy	Polina Stepensky	P1	CC (43)
ct103a cells Idiopathic Inflammatory Myopathy	Tongji Hospital	Early P1	C (39)
Cyclophosphamide Idiopathic Inflammatory Myopathy	Tongji Hospital	Early P1	C (39)
Fludarabine Idiopathic Inflammatory Myopathy	Tongji Hospital	Early P1	C (39)
her2bbζ/cd19t+ t cells Idiopathic Inflammatory Myopathy	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Early P1	C (39)